The Bio Report
Teaching Tolerance to Address Autoimmune Diseases
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:36:25
- Mas informaciones
Informações:
Sinopsis
The traditional approach to treating autoimmune disease has relied on ways to suppress the immune system. COUR Pharmaceuticals is developing first-in-class therapies that instead seek to reprogram the immune system to create antigen-specific tolerance. We spoke to COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy, about how the company’s immune-modifying nanoparticles work, how the approach preserves the immune response, and its partnership with Takeda focused on celiac disease.